Internal Reference Number: FOI_7917
Date Request Received: 03/05/2024 00:00:00
Date Request Replied To: 10/05/2024 00:00:00
This response was sent via: By Email
Request Summary: Biologic medicines in dermatology
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Deucravacitinib • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab | |
| Answer To Question 1: • Adalimumab – Humira <5 • Adalimumab Biosimilar 29 • Apremilast <5 • Bimekizumab <5 • Brodalumab 8 • Certolizumab <5 • Deucravacitinib 0 • Dimethyl fumarate 0 • Etanercept – Enbrel 0 • Etanercept Biosimilar 0 • Guselkumab 11 • Infliximab – Remicade 0 • Infliximab Biosimilar 0 • Ixekizumab 5 • Risankizumab 7 • Secukinumab <4 • Tildrakizumab 9 • Ustekinumab 14 | |
| Question Number 2: How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following: • Adalimumab - Humira • Adalimumab Biosimilar • Bimekizumab • Certolizumab • Infliximab - Remicade • Infliximab Biosimilar • Secukinumab • Ustekinumab | |
| Answer To Question 2: Adalimumab biosimilar <5 Zero for all the other biologics listed. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
